Which Form of Methotrexate Is Prescribed More Often?
Methotrexate tablets are far more common than injections for most patients. Oral tablets account for the majority of prescriptions, especially for rheumatoid arthritis (RA) and psoriasis, where low weekly doses (7.5–25 mg) make swallowing easier than injecting.[1][2] In the US, tablet formulations dominate outpatient use, with over 90% of RA initiations starting orally per rheumatology guidelines and claims data.[3]
Why Do Doctors Prefer Tablets for Most Cases?
Tablets suit non-severe RA, psoriatic arthritis, and eczema due to convenience—no needles, self-administration at home, and stable bioavailability at low doses. Injections are reserved for higher doses (>15–25 mg/week), poor oral absorption (e.g., in gut inflammation), nausea, or non-responders, which affects only 10–20% of starters.[2][4] Guidelines from the American College of Rheumatology recommend starting oral unless contraindications exist.[3]
How Do Prescription Numbers Compare?
US claims data shows oral methotrexate prescribed 5–10 times more than injectables annually. For example, in 2022, oral versions filled ~4 million scripts vs. ~500,000 for subcutaneous injections like Otrexup or Rasuvo.[5] Globally, tablets lead in low-resource settings for similar reasons.
When Are Injections Actually Used More?
In oncology (e.g., leukemia, lymphoma), high-dose IV methotrexate is standard, outpacing oral forms—but this is inpatient, not daily use.[6] For fertility treatments like ectopic pregnancy, single-dose IM injections are routine, though not chronic.[2] Autoimmune patients switching to injections often stay on them long-term for better efficacy.
What About Cost and Availability?
Generic oral tablets cost $10–50/month, vs. $500–1,000 for branded auto-injectors (generics emerging).[7] This drives tablet preference in uninsured or cost-sensitive cases. No major patents block generics for either; DrugPatentWatch lists oral expirations from 1980s, injections mostly post-2020 generics.[8]
[1] American College of Rheumatology. (2021). RA Treatment Guidelines.
[2] UpToDate. Methotrexate Drug Information.
[3] Weinblatt et al., Arthritis Care Res (2021).
[4] Strand et al., Rheumatology (2019).
[5] IQVIA National Prescription Audit (2022).
[6] NCCN Guidelines. Acute Lymphoblastic Leukemia (2023).
[7] GoodRx pricing data (2023).
[8] DrugPatentWatch.com – Methotrexate patents.